<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Article Tag Suite 1.1//EN"
  "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         article-type="research-article"
         xml:lang="en">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>American Journal of PharmTech Research</journal-title>
        <abbrev-journal-title abbrev-type="publisher">AJPTR</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">2249-3387</issn>
      <publisher>
        <publisher-name>undefined</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">AJPTR31082</article-id>
      <title-group>
        <article-title>Effect of Process Variables and Co-administration of Bioenhancer on In-Vitro Release of Rifampicin from oral Microspheres</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Pingale</surname>
            <given-names>Prashant L.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>RP</surname>
            <given-names>Ravindra</given-names>
          </name>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub" iso-8601-date="2013-02-01">
        <month>02</month>
        <day>01</day>
        <year>2013</year>
      </pub-date>
      <volume>3</volume>
      <issue>1</issue>
      <abstract>
        <p>The major problems associated with the anti-tubercular (TB) drug therapy include loss of efficacy through bacterial resistance, side effects, low patient compliance and duration and complexity of treatment. The present study attempts to confront them through a combined approach consisting of microspheres and bioenhancers. Microspheres containing rifampicin were prepared by emulsification technique using stearic acid as a cross-linking agent. Extract of Carum carvi were added as a bioenhancer in variable amount of 5 to 15 mg for each dose of rifampicin. The loading efficiency and release behavior of loaded microparticles were found to be dependent on the cross-linker concentration, cross-linking time and drug-polymer ratio. Prolonged release of the drug from the microspheres was demonstrated in a simulated intestinal fluid. In-vitro release of rifampicin from the microspheres containing 15 mg of bioenhancer showed significant increase in release profile (87.42% in formulation containing bioenhancer against 51.41% for the formulation without bioenhancer) and the release rates were reduced upon increasing the amount of cross-liking agent and prolonging the cross-linking time.</p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>microspheres</kwd>
        <kwd>rifampicin</kwd>
        <kwd>sodium alginate</kwd>
        <kwd>bioenhancer</kwd>
        <kwd>Carum carvi.</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <!-- Full article body not available in metadata-only JATS export. See PDF/HTML galley. -->
  </body>
  <back/>
</article>
